Search the Newsreel

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

Oaktree Specialty Lending Corp (OCSL) Insider Armen Panossian Bu

Okta (OKTA) Could Be 3% Above Fair Value Following The JMP Upgrade

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Okta (OKTA) moved into focus after Citizens JMP Securities upgraded the cybersecurity company to Market Outperform, citing its role in securing identity for …

Jack In The Box (JACK) Stock Profit Holds Up As Debt Strain Lingers

Hapag-Lloyd AG (HPGLY) (Q2 2026) Earnings Call Highlights: Strong Recovery with EBITDA Up 68% ...

This article first appeared on GuruFocus. Revenue: Group revenue increased by 19% quarter-on-quarter to $5.8 billion in Q2. EBITDA: Group EBITDA increased by 68% quarter-on-quarter to $829 million, with the EBITDA margin recovering from 10% in Q1 to 14.2% in Q2. EBIT: Group EBIT …

Oaktree Specialty Lending CEO Armen Panossian Acquires 1,700 Shares at $12.69 Each

Oaktree Specialty Lending Corp CEO and Co-Chief Investment Officer Armen Panossian acquired 1,700 shares of the company's common stock on August 12, 2026, at a price of $12.6945 per share. This open-market purchase increased his direct holdings to 22,489 shares. The transaction was officially …

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

ZORLU ENERJI ELE - KAP Haberleri - 2026-08-13 tarihli

Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations

Aktis Oncology (NASDAQ:AKTS) recently reported its earnings, meeting the consensus estimate for EPS at ($0.44) and surpassing revenue expectations with $3.38 million. Despite the positive earnings surprise, the stock traded down 0.9% to $23.79, giving the company a market capitalization of approximately $1.27 billion. …

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Wellington group discloses 19.4M-share KT Corporation (KT) position on 13G/A

Wellington Management Group LLP and its related entities have disclosed a beneficial ownership of 19,402,304 shares in KT Corporation (KT), representing 8.05% of the outstanding common stock, according to an amended Schedule 13G filing. The shares are held by clients of Wellington's investment advisers, …

Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend

Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (NASDAQ: OACC) Stock Price, News & Analysis

This article provides an overview of Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (NASDAQ: OACC), including its current stock price, fundamental data, and a disclaimer about the information provided. As of the last update, OACC was trading at $10.80, up 0.37%. …

Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029

Aktis Oncology reported its Q2 2026 results, highlighting progress in its targeted radiopharmaceutical pipeline with promising early data for AKY-2519 and ongoing trials for AKY-1189. The company maintains a strong financial position with $517.3 million in cash, cash equivalents, and marketable securities, projected to …

Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026

Aktis Oncology reported its financial results and business highlights for the second quarter of 2026, showcasing strong execution and progress in its clinical pipeline. The company presented promising first-in-human clinical imaging and dosimetry data for AKY-2519 and is actively enrolling patients in Phase 1b …

Citizens Just Upgraded OKTA Ahead of Upcoming Catalysts. How to View OKTA Stock Now.

The Wall Street sign is seen outside the New York Stock Exchange by hapabapa via iStock Okta (OKTA) stock has delivered one of the more striking moves in software this year. Its shares have climbed 93.8% over the past three months. That sharp re-rating …

Jack In The Box Inc. Stock 12‑Month Price Target Raised to $19.38, Implies 3% Upside

Analysts have raised the average 12-month price target for Jack In The Box Inc. (JACK) stock from $16.35 to $19.38, suggesting a 3% potential upside based on the Aug. 12 closing price. Despite this increase, the consensus rating from 17 analysts remains a "Hold," …

Orge Enerji’nin ilk yarı net karı yüzde 93,5 arttı

Orge Enerji’nin 2026 yılı ikinci çeyrek faaliyet raporu yayımlandı

NKT A/S aktualisiert Ergebnisprognose für 2026

Investors Buy Large Volume of Jack In The Box Call Options (NASDAQ:JACK)

Investors showed significant interest in Jack In The Box (NASDAQ:JACK) call options, with trading volume spiking 332% above average. This comes amidst recent insider stock purchases, increased institutional investment, and mixed analyst sentiment with an average "Hold" rating despite the company beating EPS estimates …

JACK Q3 Earnings Top Estimates, Revenues Miss as Same-Store Sales Fall

Jack in the Box Inc. JACK posted operating earnings of 96 cents per share in the third quarter of fiscal 2026, down 7.7% from $1.04 a year ago, but beat the Zacks Consensus Estimate of 90 cents by 6.7%. Restaurant-level margin edged lower amid …

Why is Jack In The Box stock surging today?

Jack In The Box Inc. (JACK) stock surged 17.0% in pre-open trading after the fast-food chain exceeded fiscal third-quarter earnings expectations. This performance, coupled with positive analyst revisions from RBC Capital and Mizuho, and significant short interest, fueled a sharp increase in share price. …

Nektar earnings in focus as Phase 3 trial launch raises stakes

Nektar Therapeutics is preparing to report second-quarter results, with analysts anticipating a loss of $2.00 per share on revenues of $10.38 million. The report comes as the company launched two pivotal Phase 3 trials for its lead drug candidate, rezpegaldesleukin, drawing investor attention to …

RWE Aktiengesellschaft Q2 Earnings Call Highlights

Key Points Interested in RWE Aktiengesellschaft? Here are five stocks we like better. RWE raised its outlook after strong first-half results, with adjusted EPS rising more than 60% to €1.77. The company now targets 2026 adjusted EPS of €2.95 and introduced 2027 guidance of …

Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up?

Nektar Therapeutics (NKTR) has experienced significant stock momentum, with year-to-date returns of 75.1% and a 1-year total shareholder return of 195.61%, despite a negative five-year record. The company's stock, currently at $76.03, is considered undervalued by one narrative, with a fair value of $153.25, …

Secunet: Das Auftragsbuch wiegt schwerer als der Umsatz

BofA Adjusts Price Target on Jack in the Box to $22 From $19

BofA has increased its price target for Jack in the Box (JACK) from $19 to $22. This adjustment reflects a positive outlook from the analyst firm for the restaurant company. The article notes this change amidst other analyst updates for Jack in the Box.

Sakthi Sugars Q1 Results: Revenue up 25% YoY to ₹376.9 crore

HHLA: Umbau der Hamburger Terminals belastet Ergebnis

Sakthi Sugars reports standalone net loss of Rs 1.83 crore in the June 2026 quarter

JTEKT India shares fall 8% after Q1 profit drops over 42.5%